Lazard Asset Management LLC Travere Therapeutics, Inc. Transaction History

Lazard Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$7.64 - $17.25 $344,090 - $776,905	-45,038 Reduced 79.15%	11,862 $106,000
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $681,079 - $1.01 Million	-44,515 Reduced 43.89%	56,900 $873,000
Q1 2023 May 15, 2023	SELL	$17.82 - $22.89 $430,780 - $553,342	-24,174 Reduced 19.25%	101,415 $2.28 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $2.32 Million - $3.28 Million	125,589 New	125,589 $2.64 Million
Q2 2022 Aug 09, 2022	SELL	$20.94 - $30.01 $1,067 - $1,530	-51 Reduced 6.76%	703 $17,000
Q1 2022 May 13, 2022	SELL	$23.61 - $30.6 $101,499 - $131,549	-4,299 Reduced 85.08%	754 $19,000
Q4 2021 Feb 09, 2022	BUY	$24.34 - $31.17 $14,068 - $18,016	578 Added 12.92%	5,053 $156,000
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $58,085 - $112,009	4,475 New	4,475 $108,000
Q1 2021 May 14, 2021	SELL	$23.37 - $31.77 $84,505 - $114,880	-3,616 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$19.17 - $27.87 $69,318 - $100,777	3,616 New	3,616 $98,000

198

84.9M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.